Download PDF
Dtsch Med Wochenschr 2005; 130(25/26): 1547-1551
DOI: 10.1055/s-2005-870861
Klinischer Fortschritt

© Georg Thieme Verlag Stuttgart · New York

Gastroenterologie/Hepatologie - Licht und Dunkel im Verdauungstrakt

Effekte von Technik, Genetik und BiologieGastroenterology/hepatology - Light and darkness in the digestive tractDevelopments by technology, genetics and biologyJ. Schölmerich1 , J. F. Riemann2
  • 1Klinik und Poliklinik für Innere Medizin I der Universität Regensburg
  • 2Medizinische Klinik C, Klinikum der Stadt Ludwigshafen gGmbH
Further Information

Publication History

Publication Date:
16 June 2005 (online)

Also available at
    Permissions and Reprints

Die letzten Jahrzehnte haben faszinierende neue Entwicklungen im Bereich der Medizintechnik ebenso wie der Genetik und der Molekular- und Zellbiologie ergeben. Von Zeit zu Zeit muss daher gefragt werden, inwieweit sich diese neuen Erkenntnisse aus der Grundlagenforschung in klinisch fassbare Fortschritte haben umsetzen lassen. Dies kann hier nur in summarischer Weise geschehen, wobei einzelne Aspekte nach zweifelsohne subjektiver Auswahl hervorgehoben werden.

Literatur

  • 1 Schiefke I, Zabel-Langhennig A, Neumann S, Feisthammel J, Moessner J, Caca K. Long term failure of endoscopic gastroplication (EndoCinch).  Gut. 2005;  54 752-758
    Google Scholar
  • 2 Barr H, Stone N, Rembacken B. Recent advances in clinical practice: Endoscopic therapy of Barett’s oesophagus.  Gut. 2005;  54 875-884
    Google Scholar
  • 3 Dulai G S, Shekelle P G, Jensen D M, Spiegel B MR, Chen J, Oh D, Kahn K L. Dysplasia and risk of further neoplastic progression in a regional veterans administration Barrett’s cohort.  Am J Gastroenterol. 2005;  100 775-783
    Google Scholar
  • 4 Spechler S J. Dysplasia in Barrett’s esophagus: limitations of current management strategies.  Am J Gastroenterol. 2005;  100 927-935
    Google Scholar
  • 5 Crowe S E. Helicobacter infection, chronic inflammation, and the development of malignancy.  Curr Opin Gastroenterol. 2005;  21 32-38
    Google Scholar
  • 6 Nardone G, Rocco A, Malfertheiner P. Helicobacter pylori and molecular events in precancerous gastric lesions.  Aliment Pharmacol Ther. 2004;  20 261-270
    Google Scholar
  • 7 Chan A O, Lam S K, Wong B C. et al . Promoter methylation of E-cadherin gene in gastric musoca associated with Helicobacter pylori infection and in gastric cancer.  Gut. 2003;  52 261-270
    Google Scholar
  • 8 Carneiro F, Huntsman D G, Smyrk T C. et al . Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening.  J Pathol. 2004;  203 681-687
    Google Scholar
  • 9 Higashi H, Nakaya A, Tsutsumi R. et al . Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation.  J Biol Chem. 2004;  279 17 205-17 216
    Google Scholar
  • 10 Rad R, Dossumbekova A, Neu B. et al . Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection.  Gut. 2004;  53 1082-1089
    Google Scholar
  • 11 Graham D Y, Shiotani A. The time to eradicate gastric cancer is now.  Gut. 2005;  54 735-738
    Google Scholar
  • 12 Nagar A B, Gorelick F S. Acute pancreatitis.  Curr Opin Gastroenterol. 2004;  20 439-443
    Google Scholar
  • 13 DiMagno M J, DiMagno E P. Chronic pancreatitis.  Curr Opin Gastroenterol. 2004;  20 444-451
    Google Scholar
  • 14 Kim K P, Kim M H, Song M H, Lee S S, Seo D W, Lee S K. Autoimmune chronic pancreatitis.  Am J Gastroenterol. 2004;  99 1605-1616
    Google Scholar
  • 15 Arvanitakis M, Delhaye M, De Maertelaere V. et al . Computer tomography and magnetic resonance imaging in the assessment of acute pancreatitis.  Gastroenterology. 2004;  126 715-723
    Google Scholar
  • 16 Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease.  N Engl J Med. 2004;  350 2383-2397
    Google Scholar
  • 17 Sass D A, Chang P, Chopra K B. Nonalcoholic fatty liver disease: a clinical review.  Dig Dis Sci. 2005;  50 171-180
    Google Scholar
  • 18 Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed?.  J Hepatol. 2005;  42 12-14
    Google Scholar
  • 19 Adams L A, Schuyler S, Lindor K D, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.  J Hepatol. 2005;  42 132-138
    Google Scholar
  • 20 Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler C F, Patsch J R, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis.  Gut. 2005;  54 117-121
    Google Scholar
  • 21 Javor E D, Ghany M G, Cochran E K, Oral E A, DePaoli A M, Premkumar A, Kleiner D E, Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.  Hepatology. 2005;  41 753-760
    Google Scholar
  • 22 Adams L A, Zein C, Angulo P, Lindor K D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.  Am J Gastroenterol. 2004;  99 2365-2368
    Google Scholar
  • 23 Uygun A, Kadayifci A, Isik A T, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis.  Aliment Pharmacol Ther. 2004;  19 537-544
    Google Scholar
  • 24 Nair S, Diehl A M, Wiseman M, Farr G H, Perrillo R P. Metformin in the tretment of non-alcoholic steatohepatitis: a pilot label trial.  Aliment Pharmacol Ther. 2004;  20 23-28
    Google Scholar
  • 25 Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease.  Nat Clin Pract Gastr. 2005;  2 148-155
    Google Scholar
  • 26 Charlton M. Nonalcoholic Fatty liver disease: a review of current understanding and future impact.  Clin Gastroenterol Hepatol. 2004;  2 1048-1058
    Google Scholar
  • 27 Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke-Schlieker W, Hellerbrand C, Kuth J, Schanz S, Kahl S, Fleig W E, Sauerbruch T. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis.  Hepatology. 2004;  40 65-72
    Google Scholar
  • 28 Sarin S K, Wadhawan M, Agarwal S R, Tyagi P, Sharma B C. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding.  Am J Gastroenterol. 2005;  100 797-804
    Google Scholar
  • 29 Garcia-Tsao G. Portal hypertension.  Curr Opin Gastroenterol. 2005;  21 313-322
    Google Scholar
  • 30 Llovet J M. Updated treatment approach to hepatocellular carcinoma.  J Gastroenterol. 2005;  40 225-235
    Google Scholar
  • 31 Bruix J, Sala M, Llovet J M. Chemoembolization for hepatocellular carcinoma.  Gastroenterology. 2004;  127 S179-S188
    Google Scholar
  • 32 Bernatik T, Becker D, Neureiter D, Hansler J H, Frieser M, Schaber S, Wein A, Hahn E G, Strobel D. Hepatic transit time of an echo enhancer: an indicator of metastatic spread to the liver.  Eur J Gastroenterol Hepatol. 2004;  16 313-317
    Google Scholar
  • 33 Schlottmann K, Kratzer W, Schölmerich J. Doppler ultrasound and intravenous contrast agents in gastrointestinal tract disorders: current role and future implications.  Eur J Gastroenterol Hepatol. 2005;  17 263-275
    Google Scholar
  • 34 Tsai C J, Leitzmann M F, Willet W C, Giovannucci E L. Dietary carbohydrates and glycaemic load and the incidence of symptomatic gall stone disease in men.  Gut. 2005;  54 823-828
    Google Scholar
  • 35 Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier.  Nat Rev Genet. 2005;  6 376-388
    Google Scholar
  • 36 Török H P, Glas J, Tonenchi L, Lohse P, Müller-Myhsok B, Limbersky O, Neugebauer C, Schnitzler F, Seiderer J, Tillack C, Brand S, Brünnler S, Jagiello P, Epplen J T, Griga T, Klein W, Schiemann U, Folwaczny M, Ochsenkühn T, Folwaczny C. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn’s disease.  Gut. 2005;  im Druck
    Google Scholar
  • 37 Noble C L, Nimmo E R, Drummond H, Smith L, Arnott I D, Satsangi J. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population.  Gut. 2005;  im Druck
    Google Scholar
  • 38 Watanabe T, Kitani A, Murray P J, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.  Nat Immunol. 2004;  5 776-778
    Google Scholar
  • 39 Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger K R, Stallmach A, Noack F, Fritz P, Schroder J M, Bevins C L, Fellermann K, Stange E F. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression.  Gut. 2004;  53 1558-1560
    Google Scholar
  • 40 Kobayashi K S, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell R A. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.  Science. 2005;  307 731-734
    Google Scholar
  • 41 Maeda S, Hsu L C, Liu H, Bankston L A, Iimura M, Kagnoff M F, Eckmann L, Karin M. Nod2 mutation in Crohn’s disease potentiates NF-κB activity and IL-1β processing.  Science. 2005;  307 734
    Google Scholar
  • 42 Eckmann L. Defence molecules in intestinal innate immunity against bacterial infections.  Curr Opin Gastroenterol. 2005;  21 147-151
    Google Scholar
  • 43 Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Fellermann K, Schroder J M, Stange E F. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium.  Infect Immun. 2004;  72 5750-5758
    Google Scholar
  • 44 Schölmerich J. Biological therapies. In: Bernstein, C. (Ed.): IBD-yearbook 2005: im Druck
    Google Scholar
  • 45 Ljung T, Karlen P, Schmidt D, Hellstrom P M, Lapidus A, Janczewska I, Sjoqvist U, Lofberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.  Gut. 2004;  53 849-853
    Google Scholar
  • 46 Colombel J F, Loftus E V, Tremaine W J, Egan L J, Harmsen W S, Schleck C D, Zinsmeister A R, Sandborn W J. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients.  Gastroenterology. 2004;  126 19-31
    Google Scholar
  • 47 Van den Brande J, Hommes D W, Peppelenbosch M P. Infliximab induced T lymphocyte apoptosis in Crohn’s disease.  J Rheumatol Suppl. 2005;  74 26-30
    Google Scholar
  • 48 Schreyer A G, Geissler A, Albrich H, Schölmerich J, Feuerbach S, Rogler G, Völk M, Herfarth H. Abdominal MRI after enteroclysis or with oral contrast in patients with suspected or proven Crohn’s disease.  Clin Gastroenterol Hepatol. 2004;  2 491-497
    Google Scholar
  • 49 Schreyer A G, Gölder S, Scheibl K, Völk M, Lenhart M, Timmer A, Schölmerich J, Feuerbach S, Rogler G, Herfarth H, Seitz J. Dark lumen magnetic resonance enteroclysis in combination with MRI colonography for whole bowel assessment in patients with Crohn’s disease: first clinical experience.  Inflamm Bowel Dis. 2005;  11 388-394
    Google Scholar
  • 50 Schreyer A G, Rath H C, Kikinis R, Völk M, Schölmerich J, Feuerbach S, Rogler G, Seitz J, Herfarth H. Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study.  Gut. 2005;  54 250-256
    Google Scholar
  • 51 Gölder S K, Schreyer A G, Endlicher E, Feuerbach S, Schölmerich J, Kullmann F, Seitz J, Rogler G, Herfarth H. Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease.  Int J Colorectal Dis. 2005;  im Druck
    Google Scholar
  • 52 Hartmann D, Schmidt H, Bolz G, Schilling D, Kinzel F, Eickhoff A, Huschner W, Möller K, Jakobs R, Reitzig P, Weickert U, Gellert K, Schultz H, Guenther K, Hollerbuhl H, Schoenleben K, Schulz H -J, Riemann J F. A prospective two-center study comparing wireless capsule endoscopy with intraoperative enteroscopy in patients with obscure gastrointestinal bleeding.  Gastrointest Endosc. 2005;  im Druck
    Google Scholar
  • 53 Keroack M. Video capsule endoscopy.  Curr Opin Gastroenterol. 2004;  20 474-481
    Google Scholar
  • 54 Gionchetti P, Morselli C, Rizzello F, Romagnoli R, Campieri M, Poggioli G, Laureti S, Ugolini F, Pierangeli F. Management of pouch dysfunction or pouchitis with an ileoanal pouch.  Best Pract Res Clin Gastroenterol. 2004;  18 993-1006
    Google Scholar
  • 55 Kruis W, Fric P, Pokrotnicks J, Lukas M, Fixa B, Kascak M, Kamm M A, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.  Gut. 2004;  53 1617-1623
    Google Scholar
  • 56 Hart A L, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm M A, Knight S C, Stagg A J. Modulation of human dendritic cell phenotype and function by probiotic bacteria.  Gut. 2004;  53 1602-1609
    Google Scholar
  • 57 Summers R W, Elliott D E, Urban J F, Thompson R A, Weinstock J V. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.  Gastroenterology. 2005;  128 1117-1119
    Google Scholar
  • 58 Summers R W, Elliott D E, Urban J F, Thompson R A, Weinstock J V. Trichuris suis therapy in Crohn’s disease.  Gut. 2005;  54 87-90
    Google Scholar
  • 59 Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, Kikendall J W, Kim H M, Weiss D G, Emory T, Schatzkin A, Lieberman D. Colonoscopic screening of average-risk women for colorectal neoplasia.  N Engl J Med. 2005;  352 2061-2068
    Google Scholar
  • 60 Agrawal J, Syngal S. Colon cancer screening strategies.  Curr Opin Gastroenterol. 2005;  21 59-63
    Google Scholar
  • 61 Fletcher J G, Booya F, Johnson C D, Ahlquist D. CT colonography: unraveling the twists and turns.  Curr Opin Gastroenterol. 2005;  21 90-98
    Google Scholar
  • 62 Riemann J F. Gastroenterologie: Neue Denkgebäude, faszinierende Wege und Schnittstelle zur Chirurgie.  Dtsch Med Wochenschr. 1999;  124 1546-1549
    Google Scholar

Prof. Dr. Jürgen Schölmerich

Klinik und Poliklinik für Innere Medizin I der Universität Regensburg

Klinikum

93042 Regensburg

Phone: 0941/9447000

Fax: 0941/9447002

Email: juergen.schoelmerich@klinik.uni-r.de

      >